Vis enkel innførsel

dc.contributor.authorMikkelsen, Gustav
dc.contributor.authorÅsberg, Arne
dc.contributor.authorHultström, Maria Elisabeth
dc.contributor.authorAasarød, Knut
dc.contributor.authorHov, Gunhild Garmo
dc.date.accessioned2018-01-31T09:38:38Z
dc.date.available2018-01-31T09:38:38Z
dc.date.created2017-12-21T21:58:51Z
dc.date.issued2017
dc.identifier.citationInternational Journal of Biological Markers. 2017, 32 (4), e461-e466.nb_NO
dc.identifier.issn0393-6155
dc.identifier.urihttp://hdl.handle.net/11250/2480873
dc.description.abstractBackground Patients with chronic kidney disease (CKD) may have increased plasma concentrations of some tumor markers even when no cancer is present. Previous studies have indicated that plasma concentrations of chromogranin A (CGA), cytokeratin 19 fragments (CYFRA 21-1), cancer antigen 125 (CA 125), cancer antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) are higher in patients with CKD but without cancer, than in healthy individuals, and this can make interpretation of results more complicated. The aim of this study was to establish reference limits for these markers in patients with CKD not receiving dialysis and with no clinical evidence of cancer. Methods We measured plasma concentrations in samples from 131 patients with CKD due to various etiologies and studied the association of tumor marker concentrations with estimated glomerular filtration rate (GFR) and other patient characteristics. Results Estimated reference limits for plasma CA 125, CA 19-9 and CEA were approximately the same as for healthy populations. Serum concentrations of CGA and CYFRA 21-1 correlated strongly with estimated GFR, and GFR-dependent reference limits were estimated. Conclusions GFR-dependent reference limits for CGA and CYFRA 21-1 are reported in order to support interpretation of these markers in patients with CKD.nb_NO
dc.language.isoengnb_NO
dc.publisherSAGE Publicationsnb_NO
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titleReference limits for chromogranin A, CYFRA 21-1, CA 125, CA 19-9 and carcinoembryonic antigen in patients with chronic kidney diseasenb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.description.versionpublishedVersionnb_NO
dc.source.pagenumbere461-e466nb_NO
dc.source.volume32nb_NO
dc.source.journalInternational Journal of Biological Markersnb_NO
dc.source.issue4nb_NO
dc.identifier.doi10.5301/ijbm.5000278
dc.identifier.cristin1531283
dc.description.localcode© 2017 The Authors. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License (http://www.creativecommons.org/licenses/by-nc-nd/4.0/)nb_NO
cristin.unitcode194,65,15,0
cristin.unitnameInstitutt for klinisk og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal